AU722653B2 - Intranasal vaccination against gastrointestinal disease - Google Patents

Intranasal vaccination against gastrointestinal disease Download PDF

Info

Publication number
AU722653B2
AU722653B2 AU64799/96A AU6479996A AU722653B2 AU 722653 B2 AU722653 B2 AU 722653B2 AU 64799/96 A AU64799/96 A AU 64799/96A AU 6479996 A AU6479996 A AU 6479996A AU 722653 B2 AU722653 B2 AU 722653B2
Authority
AU
Australia
Prior art keywords
toxin
composition
difficile
toxoid
immunization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU64799/96A
Other languages
English (en)
Other versions
AU6479996A (en
Inventor
Wende Lei
David M. Lyerly
Thomas P. Monath
James S. Moncrief
William D. Thomas Jr.
Francisco Torres-Lopez
Zhenxi Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Biologics LLC
Original Assignee
OraVax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OraVax Inc filed Critical OraVax Inc
Publication of AU6479996A publication Critical patent/AU6479996A/en
Application granted granted Critical
Publication of AU722653B2 publication Critical patent/AU722653B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU64799/96A 1995-07-07 1996-06-26 Intranasal vaccination against gastrointestinal disease Ceased AU722653B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49922995A 1995-07-07 1995-07-07
US08/499229 1995-07-07
PCT/US1996/010987 WO1997002835A1 (en) 1995-07-07 1996-06-26 Intranasal vaccination against gastrointestinal disease

Publications (2)

Publication Number Publication Date
AU6479996A AU6479996A (en) 1997-02-10
AU722653B2 true AU722653B2 (en) 2000-08-10

Family

ID=23984386

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64799/96A Ceased AU722653B2 (en) 1995-07-07 1996-06-26 Intranasal vaccination against gastrointestinal disease

Country Status (8)

Country Link
EP (1) EP0877623A1 (enExample)
JP (1) JPH11510793A (enExample)
CN (1) CN1195993A (enExample)
AU (1) AU722653B2 (enExample)
CA (1) CA2226392A1 (enExample)
NZ (1) NZ312876A (enExample)
WO (1) WO1997002835A1 (enExample)
ZA (1) ZA965737B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
US6585975B1 (en) * 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
KR100627635B1 (ko) * 1999-11-01 2006-09-25 뮤코 박스 홀딩 비.브이. 가축에서 유선 분비 항체를 제조하는 방법
US7074454B1 (en) 1999-11-01 2006-07-11 Mucovax Holding B.V. Production of mammary secretion antibodies in farm animals
US6974573B2 (en) 1999-11-01 2005-12-13 Mucovax Holdings, B.V. Antibody production in farm animals
GB0029919D0 (en) * 2000-12-07 2001-01-24 Chiron Spa Helicobacter pylori prime & boost vaccination
EP2161035B1 (en) * 2007-05-28 2019-08-21 Daiichi Sankyo Company, Limited Bordetella parapertussis-containing whole-cell vaccine composition
EP2198007B1 (en) * 2007-09-14 2017-10-25 Sanofi Pasteur Biologics, LLC Pharmaceutical compositions containing clostridium difficile toxoids a and b
US20110243991A1 (en) * 2008-12-03 2011-10-06 Boehringer Ingelheim Vetmedica Gmbh Process for production of vaccines
JP2013512916A (ja) * 2009-12-02 2013-04-18 タフツ ユニバーシティー 免疫原としてのＣｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅの無毒の組換えホロトキシン
ES2969952T3 (es) 2011-04-22 2024-05-23 Wyeth Llc Composiciones relacionadas con una toxina mutante de Clostridium difficile y sus procedimientos
US10364298B2 (en) 2011-11-18 2019-07-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141970A (en) * 1975-05-07 1979-02-27 Internationale Octrooimaatschappij "Octropa" B.V. Method for enhancing the resistance of new born mammalian young to gastro-intestinal infections
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US4944942A (en) * 1987-08-27 1990-07-31 Mobay Corporation Intranasal vaccination of horses with inactivated microorganisms or antigenic material
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
US5601823A (en) * 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
GB9209118D0 (en) * 1992-04-28 1992-06-10 Sb 120 Amsterdam Bv Vaccine compositions
AU4773293A (en) * 1992-07-16 1994-02-14 Oxford University Multiple particulate antigen delivery system

Also Published As

Publication number Publication date
ZA965737B (en) 1997-05-13
NZ312876A (en) 2000-06-23
CA2226392A1 (en) 1997-01-30
WO1997002835A1 (en) 1997-01-30
AU6479996A (en) 1997-02-10
JPH11510793A (ja) 1999-09-21
EP0877623A1 (en) 1998-11-18
CN1195993A (zh) 1998-10-14
EP0877623A4 (enExample) 1998-11-18

Similar Documents

Publication Publication Date Title
Torres et al. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters
Allaoui-Attarki et al. Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly (DL-lactide-co-glycolide) microspheres
Acheson et al. Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR
FI120137B (fi) Mutanttienterotoksiini, joka on tehokas ei-toksisena suun kautta annettavana adjuvanttina
AU6479996A (en) Intranasal vaccination against gastrointestinal disease
US5837825A (en) Campylobacter jejuni flagellin/Escherichia coli LT-B fusion protein
US5919463A (en) Clostridium difficle toxins as mucosal adjuvants
Ricci et al. Immunogenicity of the B monomer of Escherichia coli heat-labile toxin expressed on the surface of Streptococcus gordonii
WO2007110700A2 (en) Chlamydial antigens
EP0837692B1 (en) Clostridium difficile toxins and toxoids as mucosal adjuvants
NZ527322A (en) EHEC cell culture supernatant vaccine
EP1169456A1 (en) Recombinant toxin a/toxin b vaccine against clostridium difficile
US20030129198A1 (en) Methods to produce high levels of C. difficile toxins
US7608266B2 (en) Yersinia species compositions
JPH06292581A (ja) トレポネーマ・ヒオジセンテリエ ワクチン
US9119803B2 (en) Carious tooth vaccine and preparation method
US6036953A (en) Heterologous antigens in live cell V. cholerae strains
WO1998023763A9 (en) Heterologous antigens in live cell v. cholerae strains
AU740048B2 (en) Compositions and methods for administering borrelia burgdorferi antigens
US7049423B2 (en) Use of the RTX secretion system to achieve heterologous polypeptide secretion by Vibrio cholerae
WO2011005587A1 (en) Vaccine compositions and methods of use to protect against infectious disease
EP1372709A2 (en) Intimins for the prevention or treatment of infections: i
Producing Protective Immunity to Shiga-LikeToxin-I following Oral Immunization with Shiga-Like
US20020034515A1 (en) Proteus mirabilis-based vaccine
CA2243526A1 (en) Compositions and methods for administering borrelia burgdorferi antigens

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired